Clinical trial · Observational
Cardiac Angiosarcoma International Registry
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Primary cardiac angiosarcomas (PCA) are highly aggressive malignant heart tumors arising from the endothelial cells (ECs) lining the blood vessels of the heart and account for approximately 25%-30% of all primary cardiac malignancies. It is considered to be the most fatal and aggressive primary cardiac malignancy. This international registry aims to establish a large multicenter database of patients with cardiac angiosarcoma. Our objectives are: 1. Collect clinical data, including demographics, medical history, treatments, and outcomes, to build a comprehensive database. 2. Analyze data to evaluate and identify genetic, environmental, or lifestyle risk factors for cardiac angiosarcoma. 3. Evaluate the effectiveness of various treatments (surgery, chemotherapy, immunotherapy, radiation) to inform best practices. 4. Develop evidence-based guidelines and recommendations for prevention, diagnosis, treatment, and management based on registry data.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiac Angiosarcoma | Cardiac Angiosarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- 6-month overall survival
- timeFrame
- 6 months
Secondary outcomes (8)
- measure
- 1-year overall survival
- timeFrame
- 1 year
- measure
- 6-month progression free survival
- timeFrame
- 6 months
- measure
- 1-year progression free survival
- timeFrame
- 1 year
- measure
- 3-year progression free survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Histological Confirmation: A confirmed diagnosis of cardiac angiosarcoma through histopathological examination, including subtypes such as hemangiosarcoma and epithelioid hemangiosarcoma. * Diagnosis Timing: Eligible patients must have been diagnosed between January 2015 and January 2035. * Geographical Representation: Participants should be from diverse geographical locations to ensure a comprehensive understanding of the disease across different populations. * Treatment Status: Patients who have received any treatment (surgery, chemotherapy, immunotherapy or radiation) for cardiac angiosarcoma may be included to evaluate treatment outcomes. * Informed Consent: For prospective patients, informed consent must be obtained before they are included in the registry. * Clinical Data Availability: Relevant clinical data, including demographics, tumor characteristics (size, location), treatment regimens, and outcomes, must be available for analysis. * Follow-Up Willingness: Participants should be willing to undergo follow-up assessments as part of the registry's data collection efforts. Exclusion Criteria: * Patients who decline to provide informed consent. * Cases where cardiac involvement is secondary to another primary malignancy
References
Publications (0)
Data not yet available